Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
About the study
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV
- Positive serological test for autoantibodies against AChR
EXCLUSION CRITERIA
Exclusion Criteria:
- History of thymectomy, or any other thymic surgery within 12 months prior to Screening
- Untreated thymic malignancy, carcinoma, or thymoma
- History of Neisseria meningitidis infection
- Pregnancy, breastfeeding, or intention to conceive during the course of the study
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Generalized Myasthenia Gravis
Age (in years)
18+
Phase
Phase 3
Participants needed
254
Est. Completion Date
Jul 7, 2027
Treatment type
Interventional
Sponsor
Alexion Pharmaceuticals, Inc.
ClinicalTrials.gov identifier
NCT05556096
Study number
ALXN1720-MG-301
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?